Emergent BioSolutions stock rises on Q2 beat and guidance

Published on 09/17/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Emergent BioSolutions stock posted Q2 revenue of USD 234.3 million and EPS of USD 0.60 on September 17, 2026. MarketBeat said the consensus target is USD 10.00.

EBS, US29089Q1058, Illustration mit AI erstellt.

Emergent BioSolutions stock (ISIN US29089Q1058) is trading against a fresh earnings backdrop after the company reported second-quarter revenue of USD 234.3 million and earnings per share of USD 0.60, according to MarketBeat on September 17, 2026. The same report said that revenue topped the consensus estimate of USD 177.5 million by USD 56.8 million and EPS beat the forecast of a USD 0.08 loss by USD 0.68.

Q2 figures set the tone

For investors, the comparison is the key point: USD 234.3 million in revenue versus USD 177.5 million expected is a 32.0 percent beat, while USD 0.60 EPS versus a USD 0.08 loss shows a swing of USD 0.68. MarketBeat also said on September 17, 2026 that analysts expect USD 0.13 EPS for the current fiscal year and assign a consensus target price of USD 10.00.

That leaves the stock valuation tied to execution rather than just the headline beat. Yahoo Finance listed an average analyst target of USD 10.00, a high target of USD 12.00 and a current share price reference of USD 6.91 on September 17, 2026, which puts the average target 44.9 percent above that level.

Price stays below targets

The market now has to weigh the gap between the current quote reference of USD 6.91 and the USD 10.00 consensus target, plus the USD 12.00 high target, against the quarter's stronger-than-expected revenue and profit. That spread is wide enough to keep the stock sensitive to any follow-up on margins, cash flow and the next guidance update.

Stock at a glance

Emergent BioSolutions stock is at USD 6.91 on September 17, 2026, with a consensus target of USD 10.00 and a high target of USD 12.00. The latest reported quarter showed USD 234.3 million in revenue and USD 0.60 EPS, both measured against Q2 2026 expectations.